Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 23652308)

1.

Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study.

Urup T, Pawlak WZ, Petersen PM, Pappot H, Rørth M, Daugaard G.

Br J Cancer. 2013 May 28;108(10):1994-7. doi: 10.1038/bjc.2013.229. Epub 2013 May 7.

2.
4.

Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.

Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Strasburger C, Allolio B, Fassnacht M.

J Clin Endocrinol Metab. 2008 Jun;93(6):2057-62. doi: 10.1210/jc.2007-2564. Epub 2008 Mar 11. Erratum in: J Clin Endocrinol Metab. 2008 Aug;93(8):3230. Ritte, Christian [corrected to Ritter, Christian].

PMID:
18334586
5.

A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma.

Chua DT, Sham JS, Au GK.

Oral Oncol. 2005 Jul;41(6):589-95. Epub 2005 Apr 14. Review.

PMID:
15975521
6.

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.

Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger B, Ducreux MP; European Organisation for Research and Treatment of Cancer Gastrointestinal Group.

J Clin Oncol. 2005 Dec 20;23(36):9250-6.

7.

Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.

Kim JA, Lee J, Han B, Park SH, Park JO, Park YS, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2011 Jul;68(1):177-84. doi: 10.1007/s00280-010-1452-4. Epub 2010 Sep 28.

PMID:
20878159
8.

A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.

Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, Hung E, Steinberg SM, Bates S, Fojo T.

Cancer. 2002 May 1;94(9):2333-43.

9.

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].

Li JL, Zhang XR, Liu JW, Chen ZY, Lin YC, Wang YD, Chen Q, Nan KJ, Song SP, Han FC, Zhu YZ, Li LY, Zheng YH, Chu DT.

Zhonghua Zhong Liu Za Zhi. 2006 Apr;28(4):309-12. Chinese.

PMID:
16875636
10.

Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.

Polyzos A, Felekouras E, Karatzas T, Griniatsos J, Dimitroulis D, Polyzos K, Kontzoglou K, Mantas D, Karavokyros J, Nikiteas N, Tsavaris N, Syrigos K, Vafiadis I.

Anticancer Res. 2012 Sep;32(9):4151-6.

PMID:
22993377
11.

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.

Zalcberg J, Millward M, Bishop J, McKeage M, Zimet A, Toner G, Friedlander M, Barter C, Rischin D, Loret C, James R, Bougan N, Berille J.

J Clin Oncol. 1998 May;16(5):1948-53.

PMID:
9586914
12.

Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.

Binder D, Schweisfurth H, Grah C, Schäper C, Temmesfeld-Wollbrück B, Siebert G, Suttorp N, Beinert T.

Cancer Chemother Pharmacol. 2007 Jun;60(1):143-50. Epub 2006 Oct 10.

PMID:
17031643
13.

Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.

Kwon JH, Kim JH, Lee JA, Shin HC, Kim HJ, Song HH, Jung JY, Kim HY, Choi DR, Kim HS, Park YI, Zang DY.

Cancer Chemother Pharmacol. 2010 Oct;66(5):889-97. doi: 10.1007/s00280-009-1235-y. Epub 2010 Jan 21.

PMID:
20091311
14.

Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy.

Bednarski BK, Habra MA, Phan A, Milton DR, Wood C, Vauthey N, Evans DB, Katz MH, Ng CS, Perrier ND, Lee JE, Grubbs EG.

World J Surg. 2014 Jun;38(6):1318-27. doi: 10.1007/s00268-014-2484-4.

PMID:
24615603
15.

Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.

Iwasaki Y, Ohsugi S, Natsuhara A, Tsubokura T, Harada H, Ueda M, Arimoto T, Hara H, Yamada T, Takesako T, Kohno K, Hosogi S, Nakanishi M, Marunaka Y, Nishimura T.

Cancer Chemother Pharmacol. 2006 Dec;58(6):735-41. Epub 2006 Mar 25.

PMID:
16565832
16.

Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ.

Oncologist. 2012;17(1):13. doi: 10.1634/theoncologist.2011-0253. Epub 2011 Dec 30.

17.

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.

Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A.

Endocr Relat Cancer. 2010 Apr 21;17(2):445-53. doi: 10.1677/ERC-09-0281. Print 2010 Jun.

18.

Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.

Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, Lim HY, Im YH, Kang WK, Park K, Lee SI.

Cancer Chemother Pharmacol. 2007 Jan;59(1):17-21. Epub 2006 May 24.

PMID:
16721549
19.

Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen.

Tomasello G, Chiesa MD, Buti S, Brighenti M, Negri F, Rovere RK, Martinotti M, Buononato M, Brunelli A, Lazzarelli S, Donati G, Passalacqua R.

Tumori. 2010 Jan-Feb;96(1):48-53.

PMID:
20437857
20.

Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.

Douillard JY, Gervais R, Dabouis G, Le Groumellec A, D'Arlhac M, Spaeth D, Coudert B, Caillaud D, Monnier A, Clary C, Maury B, Mornet M, Rivière A, Clouet P, Couteau C.

Ann Oncol. 2005 Jan;16(1):81-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk